维布妥昔单抗联合环磷酰胺、多柔比星、依托泊苷和泼尼松序贯维布妥昔单抗巩固治疗CD30阳性外周T细胞淋巴瘤:一项多中心、单臂、2期研究
这项多中心单臂2期研究评估了CHEP-BV方案(环磷酰胺、多柔比星、泼尼松、维布妥昔单抗、依托泊苷)序贯维布妥昔单抗巩固治疗CD30阳性外周T细胞淋巴瘤的安全性和活性。48例可评估毒性,47例可评估疗效,CHEP-BV诱导后完全缓解率为79%(95% CI 64-89)。最常见≥3级不良事件为中性粒细胞减少(29%),无治疗相关死亡。
要点
- CHEP-BV诱导后完全缓解率达79%(95% CI 64-89)
- 最常见≥3级毒性为中性粒细胞减少(14/48,29%)
- 无治疗相关死亡,2期推荐剂量1.8 mg/kg维布妥昔单抗确认
核心结论
- 在主要为非间变性大细胞淋巴瘤的CD30阳性外周T细胞淋巴瘤患者中,CHEP-BV(联合或不联合自体造血干细胞移植)序贯维布妥昔单抗巩固治疗安全且有效。
研究设计与样本
- 多中心、国际、单臂、2期试验,在美国和加拿大5个学术中心开展。
- 纳入18岁及以上新诊断、未经治疗的CD30阳性外周T细胞淋巴瘤患者,ECOG评分0-2,器官功能充分。
- 计划给予6个周期CHEP-BV(维布妥昔单抗1.8 mg/kg静脉第1天,环磷酰胺750 mg/m2静脉第1天,多柔比星50 mg/m2静脉第1天,依托泊苷100 mg/m2每日静脉第1-3天,泼尼松100 mg每日口服第1-5天),并预防性使用G-CSF。
- 缓解患者可在自体造血干细胞移植后或CHEP-BV后直接接受维布妥昔单抗巩固治疗最多10个额外周期。
- 主要终点为3+3安全性导入期不可接受毒性(确认2期推荐剂量)和CHEP-BV诱导后完全缓解率。
主要发现
- 安全性导入期6例中1例出现不可接受毒性(广泛骨髓受累患者血小板计数<10 000/mm3),确认CHEP-BV中维布妥昔单抗2期推荐剂量为1.8 mg/kg。
- CHEP-BV完成时,47例中37例达完全缓解,完全缓解率为79%(95% CI 64-89)。
- CHEP-BV相关≥3级毒性最常见为中性粒细胞减少(14/48,29%)、白细胞减少(11/48,23%)、贫血(10/48,21%)、发热性中性粒细胞减少(10/48,21%)、淋巴细胞减少(9/48,19%)和血小板减少(9/48,19%)。
- 无治疗相关死亡。
临床怎么用
- 原文结论认为CHEP-BV(联合或不联合自体造血干细胞移植)序贯维布妥昔单抗巩固治疗在CD30阳性外周T细胞淋巴瘤患者中安全且有效。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: CD30 expression is universal in anaplastic large-cell lymphoma and is expressed in some other peripheral T-cell lymphoma subtypes. Incorporation of brentuximab vedotin into initial therapy for people with CD30-positive peripheral T-cell lymphomas prolonged progression-free survival, but there is room for improvement, especially for people with non-anaplastic large-cell lymphoma subtypes. METHODS: We conducted a multicentre, international, single-arm, phase 2 trial to evaluate the safety and activity of CHEP-BV (cyclophosphamide, doxorubicin, prednisone, brentuximab vedotin, and etoposide) followed by brentuximab vedotin consolidation in patients with CD30-expressing peripheral T-cell lymphomas across five academic centres in the USA and Canada. Adults aged 18 years or older with newly diagnosed, untreated CD30-positive peripheral T-cell lymphomas, Eastern Cooperative Oncology Group score of 0-2, and adequate organ function were eligible to receive six planned cycles of CHEP-BV (ie, 1·8 mg/kg brentuximab vedotin intravenously on day 1, cyclophosphamide 750 mg/m2 intravenously on day 1, doxorubicin 50 mg/m2 intravenously on day 1, etoposide 100 mg/m2 daily intravenously on days 1-3, and prednisone 100 mg daily orally on days 1-5) with prophylactic G-CSF. Patients who responded to the treatment could receive brentuximab vedotin consolidation for up to ten additional cycles either after autologous haematopoietic stem-cell transplantation (HSCT) or directly after CHEP-BV. The primary endpoints were unacceptable toxicity during a 3-plus-3 safety lead-in in participants who received study treatment and completed the safety evaluation period (to confirm the recommended phase 2 dose of brentuximab vedotin in CHEP-BV) and the complete response rate after CHEP-BV induction therapy in participants who received study treatment and had response evaluation. The study was registered at ClinicalTrials.gov (NCT03113500), and this cohort completed the trial. The trial is ongoing with the enrolment of a new cohort. FINDINGS: 54 patients were screened for eligibility and 48 were eligible for the study. The participants (18 [38%] women and 30 [63%] men; 34 [71%] White, four [8%] Black, five [10%] Asian, ten [21%] Hispanic, and 37 [77%] non-Hispanic people) were recruited and enrolled between Dec 4, 2017, and June 14, 2021, and followed up until Aug 25, 2023, when the database was locked for analysis. 48 participants were evaluable for toxicity, and 47 were evaluable for response (one participant died from COVID-19 before response assessment). During the safety lead-in, one of six participants had an unacceptable toxicity (ie, platelet count <10 000 per mm3 in a participant with extensive bone marrow involvement), and the proposed phase 2 dose of 1·8 mg/kg brentuximab vedotin in CHEP-BV was confirmed. At completion of CHEP-BV, 37 of 47 participants had complete response, yielding a complete response rate of 79% (95% CI 64-89). The most common CHEP-BV-related toxicities of grade 3 or higher were neutropenia (14 [29%] of 48), leukopenia (11 [23%]), anaemia (ten [21%]), febrile neutropenia (ten [21%]), lymphopenia (nine [19%]), and thrombocytopenia (nine [19%]). There were no treatment-related deaths. INTERPRETATION: In patients with mostly CD30-expressing peripheral T-cell lymphomas other than non-anaplastic large-cell lymphoma, CHEP-BV (with or without autologous HSCT) followed by brentuximab vedotin consolidation was safe and active. FUNDING: SeaGen, Leukemia and Lymphoma Society, Lymphoma Research Foundation, and the National Cancer Institute of the National Institutes of Health.
引用
- Herrera AF, Zain J, Savage KJ, et al. Brentuximab vedotin plus cyclophosphamide, doxorubicin, etoposide, and prednisone followed by brentuximab vedotin consolidation in CD30-positive peripheral T-cell lymphomas: a multicentre, single-arm, phase 2 study. Lancet Haematol. 2024. PMID: 39067464. doi:10.1016/S2352-3026(24)00171-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。